By


ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals 

STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers 

Phase 1 canine glioblastoma veterinary trial data show the promise of STING agonist as potential future therapy for human glioblastoma

Data support the advancement of ImmunoGenesis’ STING-Immune Stimulating Antibody Conjugate (ISAC) in immunologically cold tumors

See more here

By


Centers for Medicare & Medicaid Services Issues New Code for Encala® 

Code S9432 Will Provide Improved Access for Individuals with Malabsorption and Take Effect October 1, 2021

See more here

By


Renovacor Announces the Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer

Dr. Killeen joins Renovacor from BioMarin where he led the discovery and development of AAV-based gene therapies for inherited cardiac diseases 

See more here

By


Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam

Topline Data from Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) expected first quarter 2022 

BARDA extends cost-sharing contract to support the development of cefepime-taniborbactam in patients with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia (HABP/VABP)

Phase 3 clinical trial of cefepime-taniborbactam in patients with HABP/VABP scheduled to begin in 2022

See more here

By


Wellsheet Granted Patent to Make Electronic Health Records User-Friendly 

Intuitive and Predictive Workflow App for EHR:

• Reduces time spent in the EHR, which reduces physician burnout

• Reduces training time and improves productivity

• Increases clinician satisfaction by an order of magnitude

See more here

By


Melior Pharmaceuticals Announces Execution of a License Agreement for Armesocarb by Adhera Therapeutics

  • Under the terms of the license:  
    • Adhera will underwrite development of MLR-1019
    • Adhera has option to acquire MLR-1019

See more here

By


Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145

Investigational oral beta-lactamase inhibitor VNRX-7145 was well-tolerated with no safety signals up to the highest dose as a single agent

Ceftibuten/VNRX-7145 Combination Phase 1 Study Initiated with Top Line Results Expected Fourth Quarter 2021

Company Plans to Initiate Phase 3 Clinical Trial for Ceftibuten/VNRX-7145 in Second Half 2022

See more here

By


ImmunoGenesis Expands R&D, Clinical and Business Development Teams and Opens Research Laboratory

Clinical and CMC hires to ready initiation of multiple immuno-oncology clinical programs in 2022 

Proven business development expertise key to executing global clinical development strategy 

R&D hires and lab opening to facilitate critical translational research

See more here

By


Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential 

– All tested doses of REL-1017, including the maximum tolerated dose, showed a highly statistically significant difference in abuse potential vs.
oxycodone with p-values <0.001

– Company to host conference call at 8:30 AM Eastern Time today July 27, 2021

See more here

By


Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer’s Study

Safety and tolerability data for Cohort 2 of the Discover Study reviewed by Data Safety Monitoring Board, allowing the study to proceed with the final cohort

See more here